Tucson (Aug. 27, 2016) - NuvOx Pharma, a Tucson based biotechnology company, has been awarded a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health for $243,164.00 entitled, “Fibrin Targeted Microbubbles and Ultrasound for Treatment of Endocarditis.” Evan Unger, MD, co-founder of NuvOx, a co-principal investigator of the grant, said, “This project draws upon NuvOx’s expertise in nanotechnology to more effectively treat localized disease, in this case endocarditis, particularly in pediatric patients.”
By Michael Fitzhugh, (Aug. 24, 2016) - Chasing improved safety and decreased brain damage for stroke sufferers, Nuvox Pharma LLC is preparing for a fourth quarter start to a phase Ib study of NVX-208 (dodecafluoropentane emulsion), one of multiple oxygen therapeutics the company is advancing.
Tucson (Aug. 18, 2016) - Evan Unger, MD, President and CEO of NuvOx, announced that the FDA has allowed an investigational new drug application (IND) for NVX-208 (dodecafluoropentane emulsion) to be tested in a Phase Ib trial in stroke patients. The trial will be performed at the University of Arkansas Medical System in Little Rock, Arkansas under the direction of Dr. William Culp, Jonathan Fitch Distinguished Chair in Stroke.
Tucson (May 26, 2016) - Evan Unger, MD, President and CEO of NuvOx Pharma, a Tucson based biotechnology company, announced that the company has been awarded a grant from the National Cancer Institute to develop an ultrasound contrast agent to diagnose pancreatic cancer. The Phase I Small Business Technology Transfer (STTR) grant is a joint development project between NuvOx and Stanford University. The two principal investigators on the project are Drs. Unger and Juergen Willmann, MD, Chief of Body Imaging, Professor of Radiology, Stanford University, School of Medicine.
To read more news about NuvOx Pharma, please visit our news page.
To view more NuvOx Pharma publications, please visit our publication page.
This is a comprehensive presentation of the company's Oxygen Nanotechnology Platform for treating life threatening conditions.
Dr. Unger has pioneered original research, championed the clinical translation of his research products, and founded companies in the technology-based private sector to market these products. Dr. Unger's products are routinely used in clinical diagnostic tests that impact the lives of Arizonans and improve healthcare world-wide.
NuvOx Pharma's CBO, David Wilson presents life saving innovation at AZBio Expo 2013
11th in a series of interviews from the ICUS Bubble Conference
Updated Cochrane review comparing types of toothbrushes finds some difference in the short-term. [...]
Reviewers from Finland's national medicines agency study medicated skin treatments and shampoo [...]
The latest from the updated Cochrane Collaboration systematic review on exercise for people with hea [...]
A review from the US Agency for Healthcare Quality and Research (AHRQ) analyzes evidence about speci [...]
An individual patient data meta-analysis analyzes CBT website impact on moderate versus mild depress [...]